Prevalence of mental health evaluation in erectile dysfunction clinical trials
The Journal of Sexual Medicine · 04.09.2025 · 22 (9) · 1665-1672
DOI: 10.1093/jsxmed/qdaf173 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Sexual Medicine, online erschienen am 23.07.2025. Verfasst von Maya Morcos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Ottawa, Ottawa, ON K1H8L1, Canada. Hauptthemen laut MEDLINE: Erectile Dysfunction, Clinical Trials as Topic, Mental Health, Mental Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Erectile dysfunction (ED) is commonly psychogenic or may cause psychological issues, such as anxiety and depression. Nevertheless, the inclusion of mental health (MH) assessment in ED clinical trials has yet to be quantified.
Aim
To evaluate the prevalence of MH evaluation in ED clinical trials.
Methods
The brief and detailed descriptions from every clinical trial concerning ED from the US National Library of Medicine ClinicalTrials.gov database were extracted. Outcomes The number of studies which mention the terms “self-esteem”, “anxiety”, “depression”, “schizophrenia”, “emasculation”, “humiliation”, “isolation”, “loneliness”, “frustration”, “OCD”, “PTSD”, “ADHD”, “SUD”, “BPD”, “autism”, “bipolar”, “dementia”, “phobia”, “mania”, “anorexia”, “bulimia”, “insomnia”, and “delirium” were assessed.
Results
In total, 453 clinical trials were included from 1988 to 2024. Only seven of the searched MH terms were present in any clinical trial: stress (n = 3), self-esteem (n = 11), anxiety (n = 15), depression (n = 17), bipolar (n = 1), insomnia (n = 1), and isolation (n = 1). There was no temporal improvement in the prevalence of MH terms over time. Clinical Implications The limited inclusion of MH terms underscores a potential gap in addressing the psychological dimensions of ED in a clinical setting. Such considerations may enhance patient care by improving diagnosis and MH outcomes. Strengths and Limitations This study employs a replicable methodology using automated data extraction to quantify MH representation in ED trials. However, limitations include strict word-matching and an inability to extract word-context.
Conclusion
MH terms are infrequently included in ED clinical trials, which may reflect a lack of research interest in the association between ED and MH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, University of Ottawa, Ottawa, ON K1H8L1, Canada.
- Faculty of Applied Science and Engineering, University of Toronto, Toronto, ON M5S1A4, Canada.
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z1M9, Canada.
- Urology Department, Department of Surgery, University of Ottawa, Ottawa, ON K1Y4E9, Canada.
ORCID-Profile: Maya Morcos
Zitieren
APA
Morcos, M., Jeryous Fares, B., Golrokhian-Sani, A. A., Morcos, M., Flannigan, R., Breau, R. H., & Witherspoon, L. (2025). Prevalence of mental health evaluation in erectile dysfunction clinical trials. The Journal of Sexual Medicine, 22(9), 1665-1672. https://doi.org/10.1093/jsxmed/qdaf173
Vancouver
Morcos M, Jeryous Fares B, Golrokhian-Sani AA, Morcos M, Flannigan R, Breau RH, et al. Prevalence of mental health evaluation in erectile dysfunction clinical trials. The Journal of Sexual Medicine. 2025;22(9):1665-1672. doi:10.1093/jsxmed/qdaf173
BibTeX
@article{Morcos2025,
author = {Morcos, Maya and Jeryous Fares, Bassam and Golrokhian-Sani, Amir-Ali and Morcos, Marc and Flannigan, Ryan and Breau, Rodney H and Witherspoon, Luke},
title = {Prevalence of mental health evaluation in erectile dysfunction clinical trials},
journal = {The Journal of Sexual Medicine},
year = {2025},
volume = {22},
number = {9},
pages = {1665--1672},
doi = {10.1093/jsxmed/qdaf173}
}
EUVIMED